Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... by David Henderson (4612354)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”

(a) A cropped microscope image from the LIVECell test set, (b) overlayed ground-truth cell masks, and (c) a distance map computed from these cell masks. by Alexandra Dunnum VandeLoo (22209218)

Subjects:

A demonstration of SAMCell’s interface throughout the various stages of use: (a) landing page for image upload, (b) image selection and processing status, (c) visualization of segm... by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Example images from the (a) Cytoplasm dataset and (b) LIVECell dataset used for training and example images from each of our evaluation datasets, (c) PBL-HEK and (d) PBL-N2a. by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

(a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automati... by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Largest changes in influenza vaccine rates, Pre- vs. Post-COVID-19. by Tyler B. Nofzinger (21560244)

Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx by Dewan Zhao (21547445)

“…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …”

Association between flavonoid intakes and metabolic dysfunction-associated steatotic liver disease (MASLD) using a Restricted Cubic Spline regression model, adjusted for age, sex,... by Yuwei He (1565941)